With the continuous development and maturity of the SPAC market, the SPAC merger cases are constantly presented, bringing more vitality to the capital market. Here is a summary of the US NASDAQ SPAC merger case of this month:

On October 3, Baird Medical Best Medical was successfully listed on NASDAQ through the merger with SPAC ExcelFin Acquisition, under the ticker symbol BDMD. As a leader in the field of medical technology, Bud Medical is unique in the field of minimally invasive tumor treatment, and has made remarkable achievements in the exploration and application of microwave ablation technology.

On October 21, SPAC Investcorp AI Acquisition Corp. announced a merger with Bigtincan Holdings, with the combined Bigtincan Limited being listed on Nasdaq. The merger brings great value not only to Bigtincan's shareholders, but also to its customers, employees, and partners. It is also an opportunity to showcase Australia's strength in AI innovation, especially in areas such as sales support, and to position an Australian company as a global leader in enterprise software.

On October 22, SPAC Flag Ship Acquisition reached a merger agreement with South Korean-listed company GRT, where GRT ADS will be listed on Nasdaq. GRT is a Hong Kong-based company that has been developing and mass-producing a variety of optoelectronic products for more than a decade. It has been expanding in China in recent years, building several new factories and production line projects.

On October 23, SPAC DT Cloud Acquisition reached a merger agreement with biopharmaceutical company Maius Pharmaceutical, which will be listed on Nasdaq. Maius Pharmaceutical Co., Ltd. is a biopharmaceutical research and development company focusing on innovative dosage forms and targeted small-molecule chemical drugs. Its main research and development fields include anticancer drugs, autoimmune drugs and anti-infective drugs. The company's core products include small molecule chemical drug candidates and peptide drug candidates, and has independently established an integrated drug development platform combining chemical drug screening system and drug delivery system.

Compared with traditional IPO, SPAC provides target companies with a faster and more flexible way to go public, with short time, low cost and controllable risk. The SPAC model not only provides a channel for enterprises to go public quickly, but also provides financial and strategic support for the long-term development of enterprises, which helps enterprises to achieve sustained growth and market expansion. The SPAC model is favored by some enterprises because of its fast speed, relatively low cost and relatively simple process, especially for those seeking rapid access to the capital market.

Since 2009, the Group has adopted the SPAC listing model to help many smes in Asia to list overseas. We are looking forward to working with you！